Here, James C. Lo & team identify FAM20C as a key mediator of obesity-induced adipocyte dysfunction and inflammation, suggesting its inhibition as a potential therapy for Type2 Diabetes:
The figure shows visceral white adipose tissue in mice with adipocyte-specific deletion of Fam20c shifts shows lower macrophage area compared with controls.
1Division of Cardiology, Department of Medicine, Weill Center for Metabolic Health, Cardiovascular Research Institute, and.
2Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
3Helmholtz Institute for Metabolic, Obesity, and Vascular Research, Helmholtz Center Munich, University of Leipzig and University Hospital Leipzig, Leipzig, Germany.